Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer

The majority of prostate cancers are indolent, whereas a significant portion of patients will require systemic treatment during the course of their disease. To date, only high Gleason scores are best associated with a poor prognosis in prostate cancer. No validated serum biomarker has been identifie...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Dong, Zhongyun, Liu, Yin, Scott, Kieran F., Levin, Linda, Gaitonde, Krishnanath, Bracken, R. Bruce, Burke, Barbara, Zhai, Qihui Jim, Wang, Jiang, Oleksowicz, Leslie, Lu, Shan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2010
Soggetti:
Cancer Biology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2981059/
https://ncbi.nlm.nih.gov/pubmed/20837598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgq188
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi